Elsevier

Epilepsy Research

Volume 111, March 2015, Pages 85-141
Epilepsy Research

Review
Progress report on new antiepileptic drugs: A summary of the Twelfth Eilat Conference (EILAT XII)

https://doi.org/10.1016/j.eplepsyres.2015.01.001Get rights and content

Highlights

  • The Twelfth Eilat Conference on New Antiepileptic Drugs (AEDs)-EILAT XII.

  • Antiepileptic drugs in development.

  • Preclinical evaluation and clinical trials.

  • Development strategies of new AEDs.

Summary

The Twelfth Eilat Conference on New Antiepileptic Drugs (AEDs) – EILAT XII, took place in Madrid, Spain from August 31st to September 3rd 2014. About 130 basic scientists, clinical pharmacologists and neurologists from 22 countries attended the conference, whose main themes included “Conquering pharmacoresistant epilepsy”, “Innovative emergency treatments”, “Progress report on second-generation treatment” and “New methods and formulations”. Consistent with previous formats of this conference, a large part of the program was devoted to a review of AEDs in development, as well as updates on AEDs introduced since 2004. Like the EILAT X and EILAT XI reports, the current article focuses on the preclinical and clinical pharmacology of AEDs that are currently in development. These include adenosine-releasing silk, allopregnanolone (SAGE-547), AMP-X-0079, brivaracetam, bumetanide, cannabidiol, cannabidivarin, 2-deoxy-glucose, everolimus, ganaxolone, huperzine A, imepitoin, minocycline, NAX 801-2, pitolisant, PRX 0023, SAGE-217, valnoctamide and its homologue sec-butyl-propylacetamide (SPD), and VLB-01. Since the previous Eilat conference, perampanel has been introduced into the market and twelve novel potential epilepsy treatments are presented for the first time.

Section snippets

Adenosine-Releasing Silk

D. Boison
Robert Stone Dow Neurobiology Labs, Legacy Research Institute, Portland, OR, USA

Allopregnanolone (SAGE-547) Injection

S.J. Kanes1, J. Doherty1, R. Hammond1, M.A. Rogawski2, A. Robichaud1, J. Jonas1
1 Sage Therapeutics, Cambridge, MA 02142, USA2 Department of Neurology, University of California, Davis, Sacramento, CA 95817, USA

AMP-X-0079

A. Pesyan1, R.J. Porter2
1 AurimMed Pharma, Park City, Utah, USA2 University of Pennsylvania, Philadelphia, PA, USA, and USUHS, Bethesda, MD, USA

Brivaracetam (UCB 34714)

J. D'Souza1, H. Klitgaard2, A. Stockis3, J. Whitesides4
1UCB Pharma, Smyrna, GA, USA2UCB Pharma, Brussels, Belgium; 3UCB Pharma, Braine-L’Alleud, Belgium; 4UCB Pharma, Raleigh, NC, USA

Bumetanide

R.M. Pressler
Section of Clinical Neurosciences Unit, Institute of Child Health, University College London, UK

Cannabidiol

S. Wright1, K. Sommerville1+, N.A. Jones1, B.J. Whalley2
1 GW Pharma GW Research Limited, Porton Down Science Park, Salisbury, Wiltshire SP4 0JQ, UK1+ GW Pharmaceuticals and Duke University Medical School, UK2 Reading School of Pharmacy, University of Reading, Whiteknights, Reading, Berkshire RG6 6AP, UK

Cannabidivarin (GWP 420006)

N.A. Jones1, B.J. Whalley2
1 GW Pharma GW Pharmaceuticals plc, Porton Down Science Park, Salisbury, Wiltshire SP4 0JQ, UK2 Reading School of Pharmacy, University of Reading, Whiteknights, Reading, Berkshire, UK

2-Deoxy-d-glucose

T. Sutula
Department of Neurology, University of Wisconsin, Madison, WI, USA and NeuroGenomeX, Inc., Madison, WI, USA

Everolimus

P. Curatolo
Systems Medicine Department, Child Neurology and Psychiatry Unit, Tor Vergata University Hospital of Rome, Italy

Ganaxolone

G. Farfela, J. Tsaia, V. Nohriab
a Marinus Pharmaceuticals, Inc., New Haven, CT, USAb Mercer University, Atlanta, GA, USA

Huperzine A

S.D. Collins, J.T. Johnstone, S.S. Schachter
Insero Health, Inc., USA

Imepitoin

W. Löscher
Department of Pharmacology, Toxicology and Pharmacy, University of Veterinary Medicine, Hannover, Germany

Minocyciline

S. Koh
Department of Pediatrics, Ann & Robert H. Lurie, Children's Hospital of Chicago, Neurobiology Program, Stanley Manne Children's Research Institute, Northwestern University, Feinberg School of Medicine, Chicago, IL 60614, USA

NAX 810-2

H.S. Whitea,c, G. Bulajb, B.D. Kleina,c, C.S. Metcalfc, D.R. McDouglec, M.D. Smitha, L. Zhangb
a Department of Pharmacology and Toxicologyb Department of Medicinal Chemistry, College of Pharmacy, University of Utah, Salt Lake City, UT, United States; c Neuroadjuvants, Inc., Salt Lake City, UT, United States

Pitolisant (Tripolisant)

D. Kasteleijn-Nolst Trenité
University of Utrecht, The Netherlands; University Sapienza, Rome, Italy

PRX 0023 (Nalutozan)

W.H. Theodore
Clinical Epilepsy Section, National Institutes of Health, Building 10, Room 7D-43, Bethesda, MD 20892, USA

SAGE-217

A.J. Robichaud, J.J. Doherty, S.J. Kanes, G.J. Belfort, M.A. Ackley, E.C. Hoffman, R.S. Hammond, G. Martinez Botella, F.G. Salituro, J.M. Jonas
Sage Therapeutics, Cambridge, MA 02142, USA

Valnoctamide and sec-butyl-propylacetamide (SPD): Second generation drugs to valproic acid (VPA)

M. Bialer1, S. Kadosh2, B. Yagen1
1 Institute for Drug Research, School of Pharmacy, Faculty of Medicine, The Hebrew University of Jerusalem, Israel2 StatExcellence, Kfar Saba, Israel

VLB-01 (Beprodone)

M. Toumi1, A. Bakhutashvili2, A. Miller3
1 Faculte’ de Medicine, Laboratoire De Sante’ Publique, Aix Marseille Universite, Universite De La Mediterranee, Marseille, France2 Chief Scientific Officer, Marco Polo, Luxembourg3 Health Economics and Outcomes Research, Creativ Ceutical, Paris, France

YKP3089

S.J. Lee, M. Kamin, P. Ilankumaran
SK Life Science Inc., Fair Lawn, NJ, USA

References (221)

  • M. Bialer et al.

    Valproic acid – second generation

    Neurotherapeutics

    (2007)
  • D. Bitran et al.

    Anxiolytic effects of 3α-hydroxy-5α[β]-pregnan-20-one: endogenous metabolites of progesterone that are active at the GABAA receptor

    Brain Res.

    (1991)
  • E.R. Detrait et al.

    Brivaracetam does not alter spatial learning and memory in both normal and amygdala-kindled rats

    Epilepsy Res.

    (2010)
  • W.C. Drevets et al.

    Serotonin-1A receptor imaging in recurrent depression: replication and literature review

    Nucl. Med. Biol.

    (2007)
  • B.A. Ellenbroek et al.

    The other side of the histamine H3 receptor

    Trends Neurosci.

    (2014)
  • I. Elman et al.

    The effects of pharmacological doses of 2-deoxyglucose on cerebral blood flow in healthy volunteers

    Brain Res.

    (1999)
  • M.J. Gemkow et al.

    The histamine H3 receptor as a therapeutic drug target for CNS disorders

    Drug Discov. Today

    (2009)
  • M. Gillard et al.

    Binding characteristics of brivaracetam, a selective, high affinity SV2A ligand in rat, mouse and human brain: relationship to anti-convulsant properties

    Eur. J. Pharmacol.

    (2011)
  • P.H. Gordon et al.

    Efficacy of minocycline in patients with amyotrophic lateral sclerosis: a phase III randomised trial

    Lancet Neurol.

    (2007)
  • G. Hasler et al.

    5-HT1A receptor binding in temporal lobe epilepsy patients with and without major depression

    Biol. Psychiatry

    (2007)
  • K. Heo et al.

    Minocycline inhibits caspase-dependent and -independent cell death pathways and is neuroprotective against hippocampal damage after treatment with kainic acid in mice

    Neurosci. Lett.

    (2006)
  • M.B. Herd et al.

    Neurosteroid modulation of synaptic and extrasynaptic GABAA receptors

    Pharmacol. Ther.

    (2007)
  • A.J. Hill et al.

    Development of multi-electrode array screening for anticonvulsants in acute rat brain slices

    J. Neurosci. Methods

    (2010)
  • A.J. Hill et al.

    Phytocannabinoids as novel therapeutic agents in CNS disorders

    Pharmacol. Ther.

    (2012)
  • A.A. Izzo et al.

    Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb

    Trends Pharmacol. Sci.

    (2009)
  • N.A. Jones et al.

    Cannabidiol exerts anti-convulsant effects in animal models of temporal lobe and partial seizures

    Seizure

    (2012)
  • K. Kask et al.

    Allopregnanolone has no effect on startle response and prepulse inhibition of startle response in patients with premenstrual dysphoric disorder or healthy controls

    Pharmacol. Biochem. Behav.

    (2009)
  • D. Kasteleijn-Nolst Trenité et al.

    Efficacy of the histamine 3 receptor (H3R) antagonist pitolisant (formerly known as tiprolisant; BF2.649) in epilepsy: dose-dependent effects in the human photosensitivity model

    Epilepsy Behav.

    (2013)
  • J.F. Kerrigan et al.

    Ganaxolone for treating intractable infantile spasms: a multicenter, open-label, add-on trial

    Epilepsy Res.

    (2000)
  • T.G. Kokate et al.

    Neuroactive steroids protect against pilocarpine- and kainic acid-induced limbic seizures and status epilepticus in mice

    Neuropharmacology

    (1996)
  • N. Amada et al.

    Cannabidivarin (CBDV) suppresses pentylenetetrazole (PTZ)-induced increases in epilepsy-related gene expression

    Peer J.

    (2013)
  • F.R. Ames et al.

    Anticonvulsant effects of cannabidiol

    S. Afr. Med. J.

    (1986)
  • G. Bagdy et al.

    Serotonin and epilepsy

    J. Neurochem.

    (2007)
  • M. Balgård et al.

    Pharmacokinetic and behavioral effects of allopregnanolone in healthy women

    Psychopharmacology (Berl.)

    (2006)
  • D. Belelli et al.

    Neurosteroids: endogenous regulators of the GABAA receptor

    Nat. Rev. Neurosci.

    (2005)
  • D. Belelli et al.

    Extrasynaptic GABAA receptors of thalamocortical neurons: a molecular target for hypnotics

    J. Neurosci.

    (2005)
  • Y. Ben-Ari et al.

    The GABA excitatory/inhibitory shift in brain maturation and neurological disorders

    Neuroscientist

    (2012)
  • Y. Bersudsky et al.

    Valnoctamide as valproate substitute with low teratogenic potential in mania: double blind controlled clinical trial

    Bipolar Disord.

    (2010)
  • M. Bialer et al.

    Key factors in the discovery and development of new antiepileptic drugs (AEDs)

    Nat. Rev. Drug Discov.

    (2010)
  • T. Bisogno et al.

    Cloning of the first sn1-DAG lipases points to the spatial and temporal regulation of endocannabinoid signaling in the brain

    J. Cell Biol.

    (2003)
  • V. Biton et al.

    Brivaracetam as adjunctive treatment for uncontrolled partial epilepsy in adults: a phase III randomized, double-blind, placebo-controlled trial

    Epilepsia

    (2014)
  • D. Boison

    Adenosine augmentation therapy for epilepsy

  • D. Boison

    Adenosine as a modulator of brain activity

    Drug News Perspect.

    (2007)
  • D. Boison

    Adenosine kinase: exploitation for therapeutic gain

    Pharmacol. Rev.

    (2013)
  • N.R. Bordelon et al.

    Subchronic (45 day) oral toxicity study of 2-deoxy-d-glucose (2-DG) in F344 rats with a 15 day recovery period

    Int. J. Toxicol.

    (2013)
  • A. Brodsky et al.

    Safety and tolerability of brivaracetam (ucb 34714) as adjunctive treatment in adults with refractory partial-onset seizures

    Epilepsia

    (2007)
  • E. Broomall et al.

    Pediatric super-refractory status epilepticus treated with allopregnanolone

    Ann. Neurol.

    (2014)
  • E.A. Carlini et al.

    Hypnotic and antiepileptic effects of cannabidiol

    J. Clin. Pharmacol.

    (1981)
  • R.B. Carter et al.

    Characterization of the anticonvulsant properties of ganaxolone (CCD 1042; 3α-hydroxy-3β-methyl-5α-pregnan-20-one), a selective, high-affinity, steroid modulator of the γ-aminobutyric acidA receptor

    J. Pharmacol. Exp. Ther.

    (1997)
  • S. Casha et al.

    Results of a phase II placebo-controlled randomized trial of minocycline in acute spinal cord injury

    Brain

    (2012)
  • Cited by (0)

    View full text